Our group has recently published a new article in the open access journal PLoS ONE in which we have characterized the extracellular vesicles (EVs) present in the peritoneal dialysis efflux (PDE) from patients undergoing peritoneal dialysis.
Peritoneal dialysis is considered the best mid-term option for patients with chronic renal failure. However, functional failure of the peritoneal membrane force many patients to stop the treatment and start haemodialysis or have a renal transplantation. Currently, the state of the peritoneal membrane is monitored by the peritoneal equilibration test, a tedious technique that often shows changes when the membrane damage is advanced and in some cases patients’ life is at risk.
Thus, in our quest to anticipate and adapt for the best treatment for kidney failure patients, we are working on the identification of biomarkers to predict the malfunction of the peritoneal membrane sooner than the current technologies.
In this article from the REMAR group, the PhD students Laura Carreras-Planella and Jordi Soler-Majoral firstly demonstrated the feasibility of isolating EV from peritoneal dialysis derived efflux, which is currently just discarded as a waste product. The second and most promising result is that there are differences in the proteins contained in EVs from patients that have recently enrolled in peritoneal dialysis (less than 10 months) and those who have been treated for a longer period of time (more than 18 months). Therefore, we believe we can find in EVs a prognosis biomarker for peritoneal membrane damage that would help physicians to make earlier and better decisions for the patients.